<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04612062</url>
  </required_header>
  <id_info>
    <org_study_id>CCEE321A12101</org_study_id>
    <nct_id>NCT04612062</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of CEE321 in Adult Subjects</brief_title>
  <official_title>A First-in-Human Study to Determine Safety, Tolerability and Systemic Exposure of Topically Applied CEE321 Cream in Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects&#xD;
      and Subjects with Atopic Dermatitis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 27, 2020</start_date>
  <completion_date type="Actual">May 16, 2021</completion_date>
  <primary_completion_date type="Actual">May 16, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a FIH study of CEE321 in Adult Healthy Subjects (Part A) and Subjects with Atopic Dermatitis (Part B).&#xD;
Enrolment started with Healthy Subjects in Feb 2020. The protocol was amended Jul 2020 to include Atopic Dermatitis (AD) Subjects (Part B).&#xD;
Enrolment of AD Subjects in Part B is anticipated by end Oct / beginning Nov 2020.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label Study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>adverse events recorded during study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma trough concentration of CEE321</measure>
    <time_frame>day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atopic Dermatitis (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEE321</intervention_name>
    <description>CEE321 administered to all subjects</description>
    <arm_group_label>Atopic Dermatitis (Part B)</arm_group_label>
    <arm_group_label>Healthy Subjects (Part A)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria for Healthy Subjects (Part A)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Able to communicate well with the investigator to understand and comply with the&#xD;
             requirements of the study, including skin biopsies&#xD;
&#xD;
          -  Healthy male and female subjects aged ≥18 and ≤ 65 years&#xD;
&#xD;
          -  Able to comply with requirement of domiciliation at the investigational site&#xD;
&#xD;
        Key Exclusion Criteria for Healthy Subjects (Part A)&#xD;
&#xD;
          -  Subjects with a history of hypertrophic scars or keloids.&#xD;
&#xD;
          -  Any infection requiring treatment with systemic antibiotics, antivirals,&#xD;
             antiparasitics, antiprotozoals, or antifungals and/or hospitalization, isolation,&#xD;
             quarantine within 4 weeks prior to first treatment&#xD;
&#xD;
          -  Women of childbearing potential defined as all women physiologically capable of&#xD;
             becoming pregnant.&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 12 months prior to dosing&#xD;
&#xD;
        Key inclusion Criteria for Atopic Dermatitis Subjects (Part B)&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Able to communicate well with the investigator to understand and comply with the&#xD;
             requirements of the study, including skin biopsies&#xD;
&#xD;
          -  Adult male or female subjects aged ≥18 and ≤ 65 years with confirmed clinical&#xD;
             diagnosis of atopic dermatitis (AD)&#xD;
&#xD;
        Key Exclusion Criteria Atopic Dermatitis Subjects (Part B)&#xD;
&#xD;
          -  Subjects with a history of hypertrophic scars or keloids.&#xD;
&#xD;
          -  Any infection requiring treatment with systemic antibiotics, antivirals,&#xD;
             antiparasitics, antiprotozoals, or antifungals and/or hospitalization, isolation,&#xD;
             quarantine within 4 weeks prior to first treatment&#xD;
&#xD;
          -  Women of childbearing potential defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using highly effective methods of contraception&#xD;
&#xD;
          -  History of drug or alcohol abuse within the 3 months prior to dosing&#xD;
&#xD;
          -  Any skin disease that, in the opinion of the investigator, would confound the&#xD;
             diagnosis or evaluation of AD disease activity&#xD;
&#xD;
          -  Clinical significant medical condition, including psychiatric condition, which in the&#xD;
             Investigator's opinion may interfere with safety of subjects, study objectives or&#xD;
             adherence to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji</city>
        <state>Tokyo</state>
        <zip>192-0071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 27, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-Human</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Atopic Dermatitis</keyword>
  <keyword>CEE321</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

